Joint Formulary & PAD

Rasagiline mesilate - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :

Documentation

PAD Profile

ChemicalSubstance :
Rasagiline mesilate
Indication :
Parkinson's disease
Group Name :
Keywords :
Parkinsons disease, PD, monoamine-oxidase-B inhibitors, MAOB
Brand Names Include :
Azilect
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Rasagiline mesilate is used to treat.

  • No records returned.

Committee Recommendations (1)

  • Monoamine-oxidase-B inhibitors (rasagiline, selegiline), (or levodopa or dopamine agonists) are a first-line treatment option in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
  • Monoamine-oxidase-B inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.

Patients in whom Parkinson's is suspected should be referred quickly and untreated to a specialist.

Initiation may be carried out in Primary Care but only after recommendation by a specialist.
Modifications to therapy should only be carried out on specialist advice.

Prescribers are reminded to prescribe generically and not by brand.